Payment overview · 2025
General Payments
$1,800.72
93 reported records · 31 companies
Healthcare provider profile · identity verified
Takeshi Seto, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · OTTAWA, KS · NPI 1154323160
Verified facts
What the public records show
CMS Open Payments records show Takeshi Seto, M.D. received $1,800.72 in general payments during 2025 across 93 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $382.22 | 21.2% | 14 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $174.92 | 9.7% | 8 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $100.78 | 5.6% | 6 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $93.77 | 5.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $85.51 | 4.8% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $81.74 | 4.5% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $81.43 | 4.5% | 5 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $80.17 | 4.5% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $76.59 | 4.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.40 | 4.1% | 4 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.32 | 3.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.84 | 3.0% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $52.21 | 2.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.93 | 1.9% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $32.97 | 1.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.20 | 1.7% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.22 | 1.6% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $28.21 | 1.6% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $27.00 | 1.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.45 | 1.5% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $23.69 | 1.3% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $22.95 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.30 | 1.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.75 | 1.1% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $17.65 | 1.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.67 | 0.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.10 | 0.9% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $16.05 | 0.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.65 | 0.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.67 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.36 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,800.72 | 93 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $209.97 | 9 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $204.41 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $102.35 | 4 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $100.78 | 6 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $93.77 | 4 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $83.92 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $81.74 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $81.43 | 5 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $80.17 | 7 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $58.32 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.92 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.74 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.64 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $35.85 | 2 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $35.59 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.93 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $32.97 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.76 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.20 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $28.22 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $28.21 | 1 | 2025 |
Source payment records
|
|||||
| Xolair Normalized: xolair |
Biological | Genentech USA, Inc. | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $26.45 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 205 Acute Care Normalized: hillrom vest system model 205 acute care |
Device | Baxter Healthcare | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| Encore Normalized: encore |
Device | Philips North America LLC | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 90 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 278 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
278 | 60 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 850 | 201 |
| Losartan Potassium | Losartan Potassium | 399 | 100 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 278 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 269 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 267 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 227 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 221 | 41 |
| Furosemide | Furosemide | 199 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 198 | 81 |
| Prednisone | Prednisone | 198 | 109 |
| Tramadol Hcl | Tramadol Hcl | 137 | 23 |
| Atorvastatin Calcium | Atorvastatin Calcium | 132 | 33 |
| Metformin Hcl | Metformin Hcl | 119 | 27 |
| Omeprazole | Omeprazole | 117 | 27 |
| Potassium Chloride | Potassium Chloride | 117 | 43 |
| Sertraline Hcl | Sertraline Hcl | 108 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 29 |
| Cefdinir | Cefdinir | 102 | 77 |
| Gabapentin | Gabapentin | 102 | 28 |
| Ipratropium Bromide | Ipratropium Bromide | 94 | 37 |
| Eliquis | Apixaban | 90 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 79 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 78 | suppressed |
| Levofloxacin | Levofloxacin | 75 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 73 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 17 |
| Metformin Hcl Er | Metformin Hcl | 66 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | 18 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 60 | suppressed |
| Lisinopril | Lisinopril | 57 | 13 |
| Jardiance | Empagliflozin | 52 | suppressed |
| Simvastatin | Simvastatin | 51 | 12 |
| Ozempic | Semaglutide | 48 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 46 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 35 |
| Lorazepam | Lorazepam | 43 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 11 |
| Fenofibrate | Fenofibrate,micronized | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Carvedilol | Carvedilol | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | suppressed |
| Meloxicam | Meloxicam | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 13 |
| Famotidine | Famotidine | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Trimethoprim | Trimethoprim | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | 11 |
| Spironolactone | Spironolactone | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Azithromycin | Azithromycin | 24 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 13 |
| Methylprednisolone | Methylprednisolone | 20 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 17 |
| Mupirocin | Mupirocin | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Fasenra Pen | Benralizumab | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Hydroxyurea | Hydroxyurea | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Quinidine Sulfate | Quinidine Sulfate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,800.72 · 93 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Arikayce, BREZTRI, Brinsupri, CAPLYTA, CAPVAXIVE, COMIRNATY, DUPIXENT, ELIQUIS, EVENITY, EVKEEZA, Encore, FARXIGA, FASENRA, Flexitouch Plus, GARDASIL 9, Hillrom - Vest System Model 205 Acute Care, JARDIANCE, Leqembi, LifeVest, NEXLETOL, NUCALA, NURTEC ODT, Nimbl, Ohtuvayre, Omnipod, Ozempic, PREVNAR 20, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, REXULTI, Rybelsus, SMARTVEST, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VAXNEUVANCE, VOQUEZNA, WATCHMAN FLX, Wegovy, XYWAV, Xolair, YUPELRI, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error